Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316086989> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4316086989 endingPage "e323" @default.
- W4316086989 startingPage "e322" @default.
- W4316086989 abstract "Introduction: Due to the increasing incidence of Esophageal adenocarcinoma, detection and treatment of Barrett’s esophagus (BE) is critical. Radio-frequency ablation is the current standard of care, however, it is expensive with high recurrence rates. Argon Plasma Coagulation (APC) is an alternative method but is associated with perforation, stricture formation, and buried glands. Hybrid APC (hAPC) is a novel technique that combines APC with submucosal injection for eradication of BE. This is the first systematic review and meta-analysis to evaluate the efficacy and safety of hAPC in the management of BE. Methods: We performed a comprehensive literature search of major databases from inception to Nov 2021. The primary outcomes assessed were the clinical remission of intestinal metaplasia (CRIM) and clinical remission of dysplasia (CRD) of hAPC, high power APC (90W), and standard APC (30-75W). The secondary outcomes assessed were the overall adverse events, individual adverse events, and recurrence rates. Pooled estimates were calculated using random-effects models with 95% confidence interval (C.I.). The statistical analysis was done using STATA v 17.0 software (StataCorp, LLC College Station, TX). Results: The analysis included 37 studies (9 studies for hAPC, 4 studies for high power APC, 24 studies for standard APC) with a total of 1314 (265 for hAPC, 164 for high power APC, 885 for standard APC) patients. The calculated pooled rate of CRIM for hAPC was slightly higher at 92.11% than high power APC and standard APC groups. The calculated pooled rate of CRD for hAPC was higher than standard APC group as well. The calculated pooled rate of adverse events for hAPC was lower than other modalities. Stricture formation was the most common adverse event in all 3 groups. Stricture rates were lower in hAPC than in other groups. The calculated pooled rate of recurrence rate of BE for hAPC was higher than high power APC group but lower than standard APC group. Low to substantial heterogeneity was noted in our meta-analysis. (Figure) (Table) Conclusion: hAPC appears to be a safe and effective treatment modality for patients with Barrett’s esophagus with high clinical success rates and a low rate of adverse events. Further, prospective or randomized controlled trials are needed to validate our findings.Figure 1.: Outcomes of hAPC, high power APC and Standard APC in Barrett's esophagus Table 1. - Outcomes of hAPC, APC high power and standard APC in Barrett's esophagus hAPC APC high power Standard APC CRIM 92.11% (95% CI: 84.76%, 97.54%; p=0.07; I2=46.26%) 87.97%(95% CI: 63.42%, 100%;p=0.00; I2=92.31%) 80.67% (95% CI: 71.99%, 88.2%; p=0.00; I2=87.6%) CRD 99.5% (95% CI: 93.18%, 100%; p=0.81; I2=0%) -- 94.83% (95% CI: 77.85%, 100%; p=0.00; I2=63.03%) Adverse event 3.35% (95% CI: 0.76%, 7.09%; p=0.32; I2=14.59%) 6.3%(95% CI: 2.77%, 10.88%;p=0.64; I2=0%) 5.3%(95% CI: 1.86%, 9.89%;p=0.00; I2=67.26%) Recurrence 8.83%(95% CI: 4.13%, 14.68%; p=0.46; I2=0%) 6.49(95% CI: 0.05%, 19.18%; p=0.0; I2=79.58%) 14.71%(95% CI: 4.87%, 27.99%; p=0.00; I2=92.27%)" @default.
- W4316086989 created "2023-01-14" @default.
- W4316086989 creator A5004136681 @default.
- W4316086989 creator A5005551494 @default.
- W4316086989 creator A5010588866 @default.
- W4316086989 creator A5035013087 @default.
- W4316086989 creator A5073283444 @default.
- W4316086989 creator A5085514125 @default.
- W4316086989 date "2022-10-01" @default.
- W4316086989 modified "2023-09-27" @default.
- W4316086989 title "S454 Hybrid Argon Plasma Coagulation and Argon Plasma Coagulation in Barrett’s Esophagus: A Systematic Review and Meta-Analysis" @default.
- W4316086989 doi "https://doi.org/10.14309/01.ajg.0000858456.39414.fe" @default.
- W4316086989 hasPublicationYear "2022" @default.
- W4316086989 type Work @default.
- W4316086989 citedByCount "0" @default.
- W4316086989 crossrefType "journal-article" @default.
- W4316086989 hasAuthorship W4316086989A5004136681 @default.
- W4316086989 hasAuthorship W4316086989A5005551494 @default.
- W4316086989 hasAuthorship W4316086989A5010588866 @default.
- W4316086989 hasAuthorship W4316086989A5035013087 @default.
- W4316086989 hasAuthorship W4316086989A5073283444 @default.
- W4316086989 hasAuthorship W4316086989A5085514125 @default.
- W4316086989 hasBestOaLocation W43160869891 @default.
- W4316086989 hasConcept C120665830 @default.
- W4316086989 hasConcept C121332964 @default.
- W4316086989 hasConcept C121608353 @default.
- W4316086989 hasConcept C126322002 @default.
- W4316086989 hasConcept C141071460 @default.
- W4316086989 hasConcept C143998085 @default.
- W4316086989 hasConcept C191897082 @default.
- W4316086989 hasConcept C192562407 @default.
- W4316086989 hasConcept C197934379 @default.
- W4316086989 hasConcept C2775894508 @default.
- W4316086989 hasConcept C2776497702 @default.
- W4316086989 hasConcept C2777819096 @default.
- W4316086989 hasConcept C2778451229 @default.
- W4316086989 hasConcept C2778456384 @default.
- W4316086989 hasConcept C2778527123 @default.
- W4316086989 hasConcept C2778589982 @default.
- W4316086989 hasConcept C2778792578 @default.
- W4316086989 hasConcept C2781182431 @default.
- W4316086989 hasConcept C44249647 @default.
- W4316086989 hasConcept C61511704 @default.
- W4316086989 hasConcept C71924100 @default.
- W4316086989 hasConcept C90924648 @default.
- W4316086989 hasConcept C95190672 @default.
- W4316086989 hasConceptScore W4316086989C120665830 @default.
- W4316086989 hasConceptScore W4316086989C121332964 @default.
- W4316086989 hasConceptScore W4316086989C121608353 @default.
- W4316086989 hasConceptScore W4316086989C126322002 @default.
- W4316086989 hasConceptScore W4316086989C141071460 @default.
- W4316086989 hasConceptScore W4316086989C143998085 @default.
- W4316086989 hasConceptScore W4316086989C191897082 @default.
- W4316086989 hasConceptScore W4316086989C192562407 @default.
- W4316086989 hasConceptScore W4316086989C197934379 @default.
- W4316086989 hasConceptScore W4316086989C2775894508 @default.
- W4316086989 hasConceptScore W4316086989C2776497702 @default.
- W4316086989 hasConceptScore W4316086989C2777819096 @default.
- W4316086989 hasConceptScore W4316086989C2778451229 @default.
- W4316086989 hasConceptScore W4316086989C2778456384 @default.
- W4316086989 hasConceptScore W4316086989C2778527123 @default.
- W4316086989 hasConceptScore W4316086989C2778589982 @default.
- W4316086989 hasConceptScore W4316086989C2778792578 @default.
- W4316086989 hasConceptScore W4316086989C2781182431 @default.
- W4316086989 hasConceptScore W4316086989C44249647 @default.
- W4316086989 hasConceptScore W4316086989C61511704 @default.
- W4316086989 hasConceptScore W4316086989C71924100 @default.
- W4316086989 hasConceptScore W4316086989C90924648 @default.
- W4316086989 hasConceptScore W4316086989C95190672 @default.
- W4316086989 hasIssue "10S" @default.
- W4316086989 hasLocation W43160869891 @default.
- W4316086989 hasLocation W43160869892 @default.
- W4316086989 hasOpenAccess W4316086989 @default.
- W4316086989 hasPrimaryLocation W43160869891 @default.
- W4316086989 hasRelatedWork W1526014100 @default.
- W4316086989 hasRelatedWork W1545832077 @default.
- W4316086989 hasRelatedWork W2018720266 @default.
- W4316086989 hasRelatedWork W2327615825 @default.
- W4316086989 hasRelatedWork W2370088234 @default.
- W4316086989 hasRelatedWork W2376311785 @default.
- W4316086989 hasRelatedWork W2404447145 @default.
- W4316086989 hasRelatedWork W2586079920 @default.
- W4316086989 hasRelatedWork W3019182595 @default.
- W4316086989 hasRelatedWork W2151989677 @default.
- W4316086989 hasVolume "117" @default.
- W4316086989 isParatext "false" @default.
- W4316086989 isRetracted "false" @default.
- W4316086989 workType "article" @default.